Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp

Bullboard Posts

Comment by Smitty2000on Mar 01, 2018 5:40pm

114 Views

Post# 27647449

RE:Sernova Corp. (SVA, TSX-V) – On The Watch List

yup, im watching it alright. watching it continue to drop. did someone say $1 this year?
any news out on big pharma? where is all this interest the pumpers have been touting?
oh right it takes lots and lots and lots and lots of time for them to get interested.
sure glad i sold some sernova and bot choo. it will be $1 this year. probably $2

nopoo wrote: It has been a while since we’ve mentioned Sernova (SVA, TSX-V), but this is a stock that has followed an interesting pattern over the last 9 years with gradually higher highs and higher lows within a broad upsloping pattern. Subscribers should keep SVA on their radar screens because at some point over the next year it’s likely to accelerate rapidly on a major breakout.

Interestingly, SVA hit a 10-year high of 51 cents January 3 which took the stock right to the top of its upsloping channel but also to stiff resistance at a long-term downtrend line that started around 2000. Once SVA busts through the low 50’s, watch out. In the meantime, though, we’re focused on a better potential entry point – SVA closed Friday at 41.5 cents.

Sernova is a clinical-stage company developing products for the treatment of chronic debilitating diseases using therapeutic cells transplanted into an implanted medical device called the Cell Pouch™. The Cell Pouch™ forms a natural environment for the long-term survival and function of the therapeutic cells which release needed proteins or hormones. Type I diabetes represents the company’s most lucrative initial target market.

Dr. Philip Toleikis, Sernova’s President and CEO, stated in a recent news release: “We believe continuous glucose monitoring of patients may be an important and sensitive method to closely track the function of the transplanted therapeutic cells within the Cell Pouch. We are pleased with our collaborators in this study who have shown the foresight to support type 1 diabetes patients seeking treatment via next-generation regenerative medicine technologies.”

https://www.mackieresearch.com/legal/disclaimer.php